Bimagrumab, developed as BYM338, is an investigational human monoclonal antibody directed against activin type II receptors. It is worth noting at the outset that it is not a peptide in the sense the rest of this library uses — it is a full antibody — but it appears in the formulary because of its direct relevance to a problem peptide-based weight-loss therapy has created.
This guide situates Bimagrumab within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
The problem bimagrumab addresses
Rapid weight loss is not selective. A meaningful proportion of the weight lost on a GLP-1 receptor agonist is lean mass rather than fat, which is the opposite of the metabolic goal. Lean mass drives resting energy expenditure, glucose disposal, and physical function; losing it undermines both the durability of the weight loss and the patient's long-term health, and in older patients it feeds directly into frailty and fall risk.
The first-line answer is not pharmacologic. Resistance training and adequate protein intake are the established interventions, and every weight-loss prescription should travel with both. Bimagrumab represents the attempt to add a pharmacologic lever on top of that foundation.
How bimagrumab works
Skeletal muscle mass is held in check by a signaling system running through activin type II receptors. Myostatin and activins bind these receptors and act as a brake on muscle growth — the reason muscle does not grow without limit.
Bimagrumab blocks those receptors, releasing the brake. The result in trials is an increase in lean mass. What made it interesting for metabolic medicine was the accompanying observation that fat mass fell at the same time, a combination few interventions produce.
Because the mechanism is entirely distinct from incretin signaling, combining it with a GLP-1 agonist is mechanistically coherent: the GLP-1 drives energy deficit and fat loss, while receptor blockade defends the lean compartment.
What the evidence shows
Phase 2 work in patients with obesity and type 2 diabetes reported meaningful reductions in total body fat mass alongside increases in lean mass over the treatment period. Studies have also examined bimagrumab combined with semaglutide, addressing directly whether the pairing preserves lean mass during GLP-1-driven weight loss.
The results should be read with appropriate caution. These are phase 2 findings in defined populations, and increased lean mass measured by imaging is not the same as improved strength or physical function — a distinction that has undone other agents targeting muscle, and one that earlier bimagrumab work in muscle-wasting conditions ran into.
Adverse effects reported include muscle spasms, diarrhea, and acne. Long-term safety of sustained activin receptor blockade is not established.
Regulatory status
Bimagrumab is not FDA-approved for any indication. It is an investigational biologic, not an available treatment and not a compoundable substance.
Its significance for clinicians right now is conceptual rather than practical. It marks the point where the weight-loss conversation shifts from how much weight came off to what the weight was made of — and that shift is already actionable today through training and protein, regardless of whether this particular agent reaches market.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering body composition and lean-mass preservation, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →